Shares of DexCom Inc. slipped 3.69% to $69.47 Thursday, on what proved to be an all-around poor trading session for the stock ...

A company spokesperson said Dexcom plans to resolve the agency's concerns but stated no design changes were made to its ...

DexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the ...

Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...

The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...

Sales of Beta Bionics insulin pumps spiked 145% in the fourth quarter behind solid new patient starts. Elsewhere, former Masimo exec Jon Coleman joined Dexcom, and Sibionics’ CGM earned the CE mark.

The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...

DexCom Inc. closed 46.96% short of its 52-week high of $142.00, which the company achieved on March 26th.

Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...

Of the hundreds of millions of people living with diabetes, most liv. Dexcom wants to make sure they have tools to manage it.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NexGel Inc (NXGL – Research Report) and Dexcom ...

DexCom Inc. closed 48.20% below its 52-week high of $142.00, which the company reached on March 26th.